A multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of lenalidomide in the treatment of complex regional pain syndrome type 1.
Phase of Trial: Phase II
Latest Information Update: 02 Oct 2014
At a glance
- Drugs Lenalidomide (Primary)
- Indications Complex regional pain syndromes
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 27 Aug 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 21 Oct 2008 Planned end date changed from 1 Mar 2008 to 1 Apr 2008, as reported by ClinicalTrials.gov.
- 21 Oct 2008 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.